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angiogenesis and combinations of serological biomarkers are more likely
to be informative.
Methods: Using ELISA technology, we have developed a panel of
biomarkers, measured using GCLP, whose signature could act as a
surrogate clinical endpoint to evaluate of anti-angiogenesis therapy
considered alongside imaging data. A comprehensive panel of biomarkers
will be used in trials of anti-angiogenic drugs including VEGF A,C,D,
Placental Growth Factor, sKDR, FGF2, HGF, Ang 1/2, Tie 2, IL-8, SDF-1
and PDGF-B.
Results: Within the framework of the current EU legislation regarding the
validation of assays used in clinical trials, we have undertaken a program
of ‘fit for purpose, fast track’ method validation of these biomarkers as
singleplex ELISAs. Whilst many commercial kits are available, additional
validation issues include generation of external quality control samples,
assay performance within clinically relevant matrix (parallelism and dilution
linearity). In addition, stability of analytes under various storage and
transport conditions has been addressed.
Conclusions: This ‘fast track’ approach is part of a wider serum
biomarker analysis strategy which encompasses a comprehensive sample
processing, tracking and analysis system, fully audited by our Quality
Assurance team within a specialised GCLP laboratory. To discern drug-
induced change confidently, pilot clinical studies involve a number of pre-
dose baseline measurements essential in order to calculate signal to noise.
Multiplex technology will reduce blood volumes for these large numbers of
biomarkers if GCLP validation can be achieved.
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Background: Despite extensive therapy the 5-year survival rate of
advanced ovarian carcinoma remains poor. Mass spectrometry can be
used to discover new proteins associated with ovarian cancer. Recent
studies have indicated that there are still many unresolved problems
involving this technique. Our aim is to solve some of these problems and to
develop a specific protein profile in serum of patients with ovarian cancer.
Methods: For our pilot study 14 patients with newly diagnosed ovarian
adenocarcinoma and 14 patients with benign gynecological diseases were
included. Blood was collected using a strict protocol whereby samples are
frozen and stored at −80ºC immediately after collection. The samples were
processed on the CM10 and Q10 ProteinChip array using the SELDI-TOF.
Pre-processing was done comparing the method implemented in the
Ciphergen software to an adapted version of the Cromwell package. After
which we assessed the quality of the spectra using various clustering
methods. Classification was done using 5 different methods including three,
SVM, naiveBayes, DLDA and PCDA, to reliably identify the two sample
classes. The classifiers were validated with repeated random sampling
methodology.
Results: The different hierarchical clustering methods and subsequent
bootstrapping revealed that we could identify potential outliers and that
the quality of the remaining spectra was good. On average, 5 peaks are
differentially expressed between the two groups with a false discovery rate
<0.05. The class prediction obtained from the 5 different classification
methods on a 1000 random test sets has a mean error rate of 18%
(95%CI 0−50%). Although the Cromwell pre-processing method gave a
better estimation of the true m/z values compared to the pre-processing
done with the Ciphergen software the classification results are similar.
Conclusions: These results indicate that it is possible to separate patients
from controls with proteomic data and a variety of pre-processing and
classification methods.
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Background: Prostate cancer (PCA) is the most common cancer in men in
Western countries, with a significant increasing incidence. Although PSA
is a well known biomarker for prostate cancer, its diagnostic specificity
in detecting PCA from other benign prostate diseases such as benign
prostatic hyperplasia (BPH), is still debated. Several studies reported that
PCA patients present high levels of IGF-I and IGFBP-3.
The aim of the present study was to assess if the value of these biomarkers
in combination with PSA (Total or Free/Total ratio) could improve humoral
diagnostic performance in patients with PCA.
Methods: Two hundred eighty patients were included in the study. The
patients were enrolled by three General Hospitals (Venezia, Milan and
Treviso), between March 1996 and October 1999. 177 patients were
diagnosed with BPH (mean age 67 years; range 44−88 years) and
103 diagnosed with PCA (mean age 67 years; range 44−88 years)
according to clinical and pathological criteria. IGF-I and IGFBP-3 were
measured employing two commercially available immunoassays; RIA
(Biosource/Medgenix) and IRMA (DSL, Inc, Webster, Texas) respectively.
Total and Free PSA were measured using an automated instrument
(ADVIA-Centaur, Bayer). Statistical analyses were conducted using a
commercial available software.
Results: PCA patients had significantly higher Free and Total PSA values
than BPH patients (p 0.0001) and significantly lower Free PSA/Total PSA
ratio levels. In the present study we found a significant high positive
correlation between IGF-1 and IGFBP-3 (r = 0.72, p < 0.0001), but the
serum concentration of IGF-I and IGFBP-3 did not significantly differ
between patients with PCA and BPH neither considering their absolute
levels or their ratio (p = 0.5952). Free and Total PSA levels did not correlate
with IGF-1 and IGFBP-3 levels, neither in PCA patients nor in BPH
patients. Receivers Operating Curve (ROC) analysis matching PSA (total
or free/total ratio) with IGF-1 or IGFBP-3 did not show any significant
advantages, when compared to the use of PSA (Total or Free/Total ratio)
alone.
Conclusions: The present study, according to other reports, did not
confirm the usefulness of IGF-1 and IGF binding protein-3, in prostate
cancer. Total PSA or Free PSA//Total PSA is until now the most reliable
humoral tool in the diagnosis of prostate cancer.
